id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353671-xjpzhsup	Sgouros, George	Radiopharmaceutical therapy in cancer: clinical advances and challenges	2020-07-29		.txt	text/plain	14934	790	36	In a previous prospective single-centre phase II trial in men with metastatic castration-resistant prostate cancer in whom standard therapies had failed, patients who showed high expression of the PSMA target by ( 68 Ga-labelled PSMA-11) PET yielded favourable responses; patients with high [ 18 F]fluorodeoxyglucose (FDG) uptake in low-PSMA-uptake lesions were excluded. By incorporating molecular imaging to assess the impact of other therapeutics on RPT delivery and calculation of the target and normal tissue absorbed doses, the trial-and-error effort needed to optimize combination therapy for RPT agents can be substantially reduced. Aside from establishing trained practitioners, the future growth of RPT will be fuelled by continued discovery of more-specific tumour-associated targets, improvements in radiochemistry, increased and low-cost availability of radionuclides (particularly α-particle emitters) and expanded preclinical and clinical investigation of combination therapy with agents and treatment modalities that are complementary to RPT.	./cache/cord-353671-xjpzhsup.txt	./txt/cord-353671-xjpzhsup.txt